Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer
Not yet recruitingOBSERVATIONAL
Enrollment
200
Participants
Timeline
Start Date
May 30, 2024
Primary Completion Date
February 28, 2026
Study Completion Date
April 30, 2026
Conditions
Triple Negative Breast CancerNeoadjuvant ImmunotherapySensitivity
Interventions
DRUG
PD-1 inhibitor
PD-1 inhibitor combined with neoadjuvant chemotherapy
All Listed Sponsors
collaborator
Chinese PLA General Hospital
OTHER
lead
Shandong University
OTHER
NCT06448169 - Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer | Biotech Hunter | Biotech Hunter